Nutrition interventions for healthy ageing across the lifespan:a conference report by Kalache, A. et al.
 
 
 University of Groningen
Nutrition interventions for healthy ageing across the lifespan
Kalache, A.; de Hoogh, A.; Howlett, S. E.; Kennedy, B.; Eggersdorfer, M.; Marsman, D. S.;
Shao, A.; Griffiths, J. C.
Published in:
European journal of nutrition
DOI:
10.1007/s00394-019-02027-z
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Kalache, A., de Hoogh, A., Howlett, S. E., Kennedy, B., Eggersdorfer, M., Marsman, D. S., Shao, A., &
Griffiths, J. C. (2019). Nutrition interventions for healthy ageing across the lifespan: a conference report.
European journal of nutrition, 58, S1-S11. https://doi.org/10.1007/s00394-019-02027-z
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
Vol.:(0123456789) 
European Journal of Nutrition (2019) 58 (Suppl 1):S1–S11 
https://doi.org/10.1007/s00394-019-02027-z
SUPPLEMENT
Nutrition interventions for healthy ageing across the lifespan: 
a conference report
A. Kalache1 · A. I. de Hoogh2 · S. E. Howlett3 · B. Kennedy4 · M. Eggersdorfer5 · D. S. Marsman6 · A. Shao7 · 
J. C. Griffiths8
Published online: 28 June 2019 
© The Author(s) 2019
Abstract
Thanks to advances in modern medicine over the past century, the world’s population has experienced a marked increase 
in longevity. However, disparities exist that lead to groups with both shorter lifespan and significantly diminished health, 
especially in the aged. Unequal access to proper nutrition, healthcare services, and information to make informed health 
and nutrition decisions all contribute to these concerns. This in turn has hastened the ageing process in some and adversely 
affected others’ ability to age healthfully. Many in developing as well as developed societies are plagued with the dichotomy 
of simultaneous calorie excess and nutrient inadequacy. This has resulted in mental and physical deterioration, increased 
non-communicable disease rates, lost productivity and quality of life, and increased medical costs. While adequate nutrition 
is fundamental to good health, it remains unclear what impact various dietary interventions may have on improving health-
span and quality of life with age. With a rapidly ageing global population, there is an urgent need for innovative approaches 
to health promotion as individual’s age. Successful research, education, and interventions should include the development 
of both qualitative and quantitative biomarkers and other tools which can measure improvements in physiological integrity 
throughout life. Data-driven health policy shifts should be aimed at reducing the socio-economic inequalities that lead to 
premature ageing. A framework for progress has been proposed and published by the World Health Organization in its Global 
Strategy and Action Plan on Ageing and Health. This symposium focused on the impact of nutrition on this framework, 
stressing the need to better understand an individual’s balance of intrinsic capacity and functional abilities at various life 
stages, and the impact this balance has on their mental and physical health in the environments they inhabit.
Keywords Ageing · Bioactives · Biomarkers · Functional ability · Healthspan · Inequalities · Intrinsic capacity · Lifespan · 
Nutrition · Vitamins
Introduction
The World Health Organization’s (WHO) definition of 
Healthy Ageing—the process of developing and maintain-
ing the functional ability that enables wellbeing in older age 
[70]—continues to be a driver of both scientific research 
and policy advancement on ageing. The foundation of this 
definition is the functional ability of the individual, which 
This is the ninth CRN-International conference report. Previous 
conference reports were published in Regulatory Toxicology 
and Pharmacology [57], and for the last 7 years in the European 
Journal of Nutrition [1, 6, 33, 36, 37, 41, 55].
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in turn is dependent upon his/her intrinsic capacity and how 
that interacts with the environment (recently discussed in 
detail by Marsman et al. 2018) [41]. With a rapidly expand-
ing global population over the age of 65 driven in large part 
by increased life expectancy, interventions and policies are 
needed to improve the intrinsic capacity and functional abil-
ity trajectories.
The Longevity Revolution (LR) is a term used to char-
acterise the recent and rapid increase in life expectancy 
(or lifespan) overall which has not been paralleled by the 
same increase in healthspan (defined as the period of life 
spent in good health, free from the chronic diseases and 
disabilities of ageing) [25, 65]. Thus, although life expec-
tancy has increased worldwide, the intrinsic capacity and 
therefore functional ability trajectories have not improved 
simultaneously. This is especially apparent in developing 
countries where social inequalities have led to premature 
ageing, characterised by reduced healthspan and increased 
rates of chronic disease and disability. To reduce premature 
ageing and promote healthy ageing, appropriate policies and 
interventions are needed both at the individual and societal 
levels.
The impact of diet and lifestyle on health status is now 
well established. In developing countries, while undernutri-
tion (nutritional inadequacy) continues to be a public health 
challenge, it is now accompanied by over-nutrition—socie-
ties are overfed, yet undernourished, leading to the dichot-
omy of obesity in the face of nutrient inadequacy and pre-
mature ageing [55]. To foster research that will further the 
understanding of which nutritional interventions improve 
healthspan and by what mechanism, it is critical to identify 
biomarkers of ageing and healthy ageing that can be used to 
assess the impact of interventions.
Ageing research has evolved from relying on single, static 
biomarkers to a 360° systems-based approach [55, 64, 74], 
which incorporates biomarkers from a range of biological, 
psychological, functional, and even digital platforms (see 
Table 1).
Healthspace is an example of systems biology that can be 
used to assess and visualize the body’s biologic and physi-
ologic response to a stressor or intervention on self-selected 
‘axes’. The Frailty Index (FI) combines a series of func-
tional deficits as an overall indicator of intrinsic capacity. 
Technological advances have afforded the use of digital 
imageing as a means to estimate ageing by analyzing physi-
cal facial traits. These measurements collectively assess the 
body’s ability to cope mentally and physically with the stress 
of the ageing process. Using a systems-based approach and 
combining these into indices may provide a more accurate 
overall indication of healthy ageing, and can more readily 
assess the impact of different nutritional interventions which 
in turn have the potential to be personalised.
Today, well-studied diet and lifestyle interventions 
shown to increase both lifespan and healthspan are limited. 
Caloric restriction, intermittent fasting and exercise each 
have demonstrated longevity-enhancing effects which are 
highly conserved among animal models and humans [58]. 
Few other nutrition interventions have been shown to have 
these effects. In contrast, several drug compounds have been 
shown to exert effects on lifespan that mimic the effects of 
caloric restriction and exercise. Rapamycin, Metformin and 
certain non-steroidal anti-inflammatory drugs (NSAIDS) 
are known to extend both lifespan and healthspan in animal 
models by inhibition of the mammalian target of rapamycin 
(mTOR) pathway [31]. That the mechanism by which caloric 
restriction and exercise increase lifespan and healthspan is 
also highly conserved and also works through the mTOR 
pathway, suggests that there may be promise for example, 
with certain dietary components that may also affect similar 
pathways. Resveratrol [53] and alpha-ketoglutarate [12] are 
among several promising naturally-occurring compounds 
that may enhance lifespan and healthspan via a similar 
mechanism.
It is well established that nutrient inadequacy is associ-
ated with increased risk for a variety of chronic diseases, 
especially when combined with obesity. Therefore, main-
taining adequate nutrition status is important to reduce the 
risk of chronic diseases, many of which are age-related. 
However, whether achieving optimal status may also help 
delay premature ageing and support healthy ageing remains 
to be investigated.
Going forward, there is a need to establish widespread 
scientific agreement around which biomarkers are most 
indicative of healthy ageing and for additional research 
examining nutrition interventions that can positively affect 
these biomarkers. Research must also be aimed at the impact 
Table 1  Biomarkers of healthy ageing
Biomarker Description Category
Healthspace Multiple biomarkers that are combined into one or more composite scores (axes) using multivariate statistical 
methods to measure and visualize the body’s biologic response to an intervention (or stressor); serves as a com-
prehensive assessment of an individual’s health status
Biological
Frailty Index Measurement of the accumulation of a collection of functional health deficits relative to the total number of pos-
sible deficits
Functional
Facial imageing Measurement of physical changes in facial structure over time Digital
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of early nutrition interventions, well before the onset of mor-
bidity, as an approach to delay premature ageing. From a 
policy perspective, there is an urgent need to address social 
inequalities that contribute to premature ageing; interven-
tions targeted at inequality are needed both at the individual 
and societal level. There is also an opportunity to assess 
the impact of nutrition interventions on age-related issues 
beyond health, such as healthcare cost and productivity.
New paradigms in health assessment: 
360° diagnosis, phenotypic flexibility 
and composite biomarkers
It has been widely accepted that healthy living can increase 
longevity. However, health care systems still focus on disease 
and mostly reductionist, pharmacological treatments [66]. 
This approach is inefficient for treating so-called “lifestyle-
related diseases”, including metabolic syndrome, obesity, 
type-2 diabetes, and cardiovascular disease. Recent findings 
demonstrate that type-2 diabetes can even be reversed with 
long-term structural lifestyle changes [32, 62]. Also, life-
style interventions have been proven successful in reduc-
ing obesity, metabolic syndrome and cardiovascular disease 
risk [10, 34, 48]. Adopting lifestyle-related interventions in 
healthcare requires a switch from professional-driven care 
to citizen–patient-centred approaches.
Previously in 2011, Huber et al. proposed to shift the 
focus in defining health from absence of disease towards 
“the ability to adapt and self-manage in the face of social, 
physical and emotional challenges” [20]. This definition 
advocates for more attention for the individual and their 
environment, instead of only focusing on standard clinical 
parameters. In other words, health should be approached as 
a system, taking into account the complex interplay between 
genetics, metabolic processes, lifestyle, psychological health 
and the socio-economic environment [64]. Using such a sys-
tems approach is not only of importance in health research, 
but also in health care practice. Research has shown that 
factors like motivation, comorbidities, mental health (e.g., 
depression), personality traits (e.g., self-efficacy) and the 
financial situation can negatively influence health behavior 
change and self-management [3, 46]. Such factors should 
thus be taken into account in developing an individual treat-
ment plan. A so-called 360° diagnosis, ranging from per-
sonality questionnaires to sensors to sample analysis, can 
facilitate an extensive evaluation of the physical and mental 
health status of a patient, as well as their behavior and envi-
ronment. The results can be visualized in a ‘profile wheel’, 
and as such offer a snapshot overview of a patient and their 
most pressing issues, and serve as a shared decision-mak-
ing tool between patient and health care provider [64] (see 
Fig. 1).
The next challenge is to translate the results of such a 
360° diagnosis into an effective treatment plan. Regular 
exercise, healthy eating, sufficient sleep and limiting or quit-
ting unhealthy activities such as sedentary behavior, alco-
hol consumption and smoking, can contribute to increased 
lifespan and healthspan [13, 18]. However, it has recently 
been shown that individuals may respond differently to spe-
cific lifestyle interventions. For instance, type-2 diabetics 
seem to respond differently to dietary patterns, i.e., people 
with insulin resistance mainly in the liver respond better to 
a low-fat diet, whereas those with insulin resistance mainly 
in the muscles respond better to a Mediterranean diet [9]. It 
thus seems that personalization of lifestyle recommendations 
to the individual is necessary. Personalization of lifestyle 
advice on health status requires understanding of the com-
promised underlying metabolic processes for an individual 
and their ability to adapt to environmental challenges, also 
called ‘phenotypic flexibility’ [63]. A mixed-meal challenge 
test has been developed that is able to quantify phenotypic 
flexibility by measuring the responses in the pancreas, gut, 
adipose tissue, kidney, vasculature, muscle, liver, and metab-
olism as a whole using 132 different biomarkers [67]. The 
question is then, how to use the results of such a challenge 
test to determine systems flexibility?
Traditionally, single-parameter methods are used to meas-
ure aspects of flexibility, such as the oral glucose tolerance 
test. Such methods are only applicable if sufficient data from 
a range of health, disease and age conditions is available, 
which allows for establishing a desired health outcome as a 
benchmark for the measured outcome [61]. This, however, 
Fig. 1  Visualization of the “profile wheel” resulting from an exten-
sive 360° diagnosis. The profile wheel is constructed of four quad-
rants: environment, body, behavior and thinking and feeling. The 
quadrants are further split up in sub-domains, including glucose 
metabolism, body composition (body), medication use (behavior) and 
loneliness (environment). The colors represent the traffic light model, 
with green representing a healthy score for a sub-domain, orange an 
in-between state and red an unhealthy score
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is again a reductionist approach, disregarding the complexity 
of systems health. A new concept called the “health space” 
can be used to visualize optimal systems flexibility, using 
a 2-days, 3-days or even 4-days space with predefined axes 
representing relevant biological processes or health areas of 
interest. These axes each consist of multiple biomarkers that 
are combined into a single score using multivariate statisti-
cal methods. Visualizations of a health space also provide a 
valuable tool in communicating health status (as compared 
to peers) to individuals, and to show changes in health over 
time (see Fig. 2).
To conclude, health research and health care should shift 
from reductionist disease management, to integral and per-
sonal treatment plans, including lifestyle. Various methods 
are being developed that enable a better understanding and 
quantification of health, using extensive 360° diagnosis 
tools, phenotypic flexibility for unraveling the underlying 
mechanisms and personalized treatment, and composite bio-
markers as a measure of and benchmark for changes in sys-
tems flexibility. When combined, these methods can contrib-
ute to integrated, and more personalised health optimization.
Biomarkers of frailty as a measure of healthspan 
in naturally‑ageing mice
It is clear that people age at different rates, so that an indi-
vidual’s biological age can be quite different from their cal-
endar age. In other words, ageing is heterogeneous [44]. This 
has given rise to the concept of “frailty”, which is a state 
of increased vulnerability to adverse health outcomes [52]. 
Frailty is a key health care challenge because frail individu-
als are much more likely to experience poor quality of life, 
hospitalisation and death than their non-frail counterparts. 
Still, little is known about the biology of frailty, even though 
this could help understand critical determinants of health-
span and facilitate the development of novel interventions 
to treat frailty [52].
Recent research has pioneered the idea that frailty occurs 
not only in humans, but also in animal models of ageing 
(reviewed by Banga et al. [4]). Further, it has been shown 
that frailty can be quantified with a “frailty index” (FI) tool 
based on the accumulation of age-dependent health deficits; 
this technique is well established clinically and was origi-
nally developed for use in people [45]. To construct an FI, 
one can measure more than 30 readily observable signs of 
clinical deterioration in ageing mice. The number of defi-
cits in an individual mouse, divided by the total number of 
deficits measured, yields an FI score that is theoretically 
between 0 (no deficits) and 1 (all possible deficits). Key 
features of FI scores are similar in mice and people [51]. 
For example, FI scores increase with age in mice with much 
the same trajectory as in people. High frailty scores also 
predict mortality in mice as in humans, the rates of deficit 
accumulation are virtually identical in mice and humans 
and the highest FI scores in mice (FI ≈ 0.55) approach the 
submaximal limit to frailty reported in humans [51]. In addi-
tion, female mice have higher frailty scores than males [27]. 
This is similar to the morbidity–mortality paradox seen in 
humans, where women have higher FI scores than men at 
any age, but paradoxically they live longer [17].
This powerful new FI tool has been used in a variety of 
preclinical studies. Research has shown that age-dependent 
maladaptive changes in heart function are correlated with, 
and closely graded by FI score [15]. The FI score also is 
responsive to interventions, as mice treated with known 
longevity interventions (e.g., caloric restriction, resveratrol) 
have lower scores than untreated animals [26]. Other mouse 
work also shows that chronic treatment with the angiotensin-
converting enzyme (ACE) inhibitor, enalapril, attenuates 
frailty through sex-specific effects on pro- and anti-inflam-
matory cytokines [28]. Importantly, some of these findings 
in the mouse model have been translated back to humans. 
For instance, original work in mice showed that an FI could 
be developed based on routine laboratory blood work plus 
Fig. 2  Example of a health 
space, showing the muscle 
health and wellbeing of an 
elderly person as compared to 
a reference group with optimal 
health and a reference group 
with compromised health 
status (no citation, paper under 
review)
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standard clinical test results (e.g., blood pressure, heart rate) 
[49]. Based on this, similar measures were used to develop 
a laboratory-based FI tool (FI-Lab) for use in people which 
predicts mortality just like the clinical FI tool [19].
As the FI score can be objectively quantified and shown to 
reflect normal physiologic/pathologic processes or responses 
to therapeutic interventions, this tool appears to meet the 
definition of a biomarker [7]. Therefore, this suggests that 
both the clinical FI tool and the laboratory-based FI tool 
may be useful as biomarkers of frailty and healthspan in 
ageing mice. This ability to quantify frailty in animals is a 
major step forward in the effort to understand the biology 
of frailty, and provides a new platform to develop and test 
novel clinical interventions.
Impact of nutrition interventions 
on age‑related decline: animal models 
and humans
We are at an interesting juncture, where research into the 
biology of ageing seems to have defined the major determi-
nants of ageing and, more importantly, identified a robust 
and increasing number of interventions that have the poten-
tial to extend not just human lifespan but also healthspan, the 
disease-free and functional period of life [29, 35].
Interventions that may slow ageing include drugs (e.g., 
rapamycin, metformin) [5, 30], supplements (e.g., nicotina-
mide riboside, nicotinamide mononucleotide) [72], lifestyle 
interventions (e.g., exercise) [21] and diets (e.g., fasting) 
[42]. All of these and many others are reported to extend 
lifespan and/or healthspan in animal models. Moreover, 
many of these interventions have been explored in humans 
to varying degrees and in different, mostly disease-related 
contexts. While individual scientists certainly have their 
favorites, there is no consensus as to which might confer 
larger benefits and a nagging sense that ageing will ulti-
mately be personal, such that successful interventions may 
be different from one individual to the next. This raises the 
question: how can we determine which interventions will 
(1) alter the rate of human ageing, (2) keep people healthy 
and functional longer and/or (3) prevent the onset of many 
age-related diseases simultaneously.
Determining whether interventions extend human life-
span is a time- and cost-prohibitive strategy. In lieu of 
that, there are variations of two main themes. First, it is 
feasible to determine whether an intervention might protect 
against the onset of (or even reverse) an age-related dis-
ease or functional parameter linked to disease, and while 
often not favorable to the pharmaceutical industry because 
prevention trials are long and costly, this strategy has been 
tested. Perhaps most interesting are a pair of recent stud-
ies showing that mTOR inhibition by everolimus, alone 
or in combination with a mTOR catalytic inhibitor at low 
dose, can reverse aspects of immune senescence and protect 
against infections in individuals over 65 years of age [38, 
39]. More comprehensively, it is possible to test whether an 
intervention protects against multiple chronic conditions of 
ageing simultaneously and this has been proposed with the 
TAME trial, which will test the effects of metformin in older 
individuals (notably, it will also look at biomarkers of ageing 
as secondary endpoints as follows) [47]. While appealing, 
this trial will involve thousands of individuals and have high 
cost, likely precluding a widespread comparison of different 
interventions at least in the near term.
A second approach involves determining whether inter-
ventions may alter the rate of change of ageing biomark-
ers and while interventions have gotten much attention, 
recent approaches to identify minimally invasive ageing 
biomarkers are equally important. While biomarkers of a 
specific disease have long been a major focus of research, 
ageing remained refractory to such indicators until recently. 
Through analysis of deep datasets usually in large popula-
tions and artificial intelligence-based approaches [14, 73], 
several biomarkers have been proposed, including the epi-
genetic clock [16], which measures the methylation status 
of specific DNA regions in the genome, and others includ-
ing molecular markers, analysis of facial patterns, and even 
locomotor activity patterns [11, 50]. A potential advantage 
to trials using biomarkers is that they, at least in theory, (1) 
can be applied across a wider range of ages, (2) may have 
measurable effects in a shorter time window and (3) could 
be more economical, allowing for multi-intervention test-
ing. However, it is still in the early days and much remains 
speculative. For instance, it is not clear whether (1) biomark-
ers are dynamic (although initial indications suggest this to 
be true), (2) biomarkers can be reversed or only changed in 
trajectory, and how (3) biomarkers relate to each other and 
disease onset. At this point, this approach is highly promis-
ing but also in its infancy.
The entry of ageing interventions into the human realm is 
exciting and potentially transformative, yet it remains under-
appreciated by key constituencies in the healthcare space. 
Government funding agencies have yet to fully embrace the 
concept, although the National Institutes of Health (NIH) 
National Institute of Ageing led Geroscience Initiative is 
encouraging [56]. Physicians, and even many geriatricians, 
remain unaware of the promise of interventions to extend 
healthspan, and others are skeptical that preventative medi-
cine can succeed. Finally, regulatory agencies have yet to 
ponder whether ageing is a disease or condition and thus at 
present there exists no clear mechanism to approve ageing 
interventions, although the US Food and Drug Administra-
tion has recently displayed an open-minded approach. It is 
easy to look at these hurdles as inhibitory toward progress, 
but another exciting development has emerged. Recently, 
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many investors have embraced the notion that human age-
ing can be delayed and have been convinced of the poten-
tial widespread quality-of-life and economic benefits that 
would accrue. Hence, private sector money has started to 
flow into the ageing space and now dozens of companies 
have emerged [56]. While no one knows the right path to 
success, the range of innovative ideas and approaches being 
tried dramatically increase the odds. Moreover, the imagina-
tion of the public is starting to be captured and it is incredu-
lous to think that successful validation of interventions to 
slow ageing will not result into widespread dissemination. 
Once a backwater in medical research, the science of human 
ageing is now in the forefront and interventions extending 
human healthspan may be the biggest medical breakthroughs 
of this century.
Supplementation’s role in assuring 
nutritional adequacy as one ages
One of mankind’s most remarkable achievements is 
increased life expectancy. Lifespan increased and continues 
to increase. Unfortunately, for many people this gain in life 
years is not matched by gain in years of healthy life. We face 
the challenge of a continuous increase of non-communicable 
diseases (NCDs) like osteoporosis, diabetes, cardiovascular 
diseases and cancer, to mention a few. There is growing evi-
dence that lifestyle factors have substantial effects on health 
and wellbeing. The risk for non-communicable diseases 
can be reduced by lifestyle changes, with improved nutri-
tion being an essential part. According to the World Health 
Organization (WHO) approximately one-third of cancers 
and up to 80% of heart disease, stroke and type-2 diabetes 
deaths are preventable [69]. To achieve this, a shift of focus 
from disease to capacity is required. Instead of diagnosing 
diseases on a point in time, trajectories across the life course 
should be monitored [41]. In this context the role and con-
tribution of nutrients for a healthy life by achieving opti-
mal status are of relevance [59]. Inadequate micronutrient 
intake and status are recognized to be an important factor 
in this context and an issue for millions. New findings and 
approaches which are used to assess the impact and benefit 
of nutrition providing an optimal nutrient status for a healthy 
life and healthy ageing six examples are further discussed:
• Improving mobility by counteracting muscle and bone 
loss.
• Supporting eye health via maintaining macular optical 
pigment density.
• Maintaining heart and vascular health via blood pressure 
and triglyceride management.
• Blood glucose management.
• Counteracting cognitive decline.
• Strengthening the immune system to reduce risk for res-
piratory tract infections.
Muscle and bone loss is a major issue in ageing. Accord-
ing to the International Osteoporosis Foundation (IOF) 
one in three women and one in five men over the age of 
50 years will sustain an osteoporotic fracture. In women, 
the incidence of fractures is higher than the total incidence 
of cancer, heart infarction, stroke or diabetes. Osteoporo-
tic fractures account for more days spent in hospitals than 
many other diseases, including diabetes, myocardial infarc-
tion, and breast cancer [23]. In several human studies, it is 
demonstrated that bone mass density increases with higher 
25-hydroxyvitamin D [25(OH)D] plasma levels which can 
be achieved via different routes [8]. In an assessment of 
health care costs it was shown that the use of vitamin D food 
supplements by all Europeans age 55 and older diagnosed 
with osteoporosis or osteopenia then €3.96 billion in avoid-
able hospitalization costs per year are potentially realizable 
[54].
Millions of people are impacted globally by the deteriora-
tion of eye health. Macular degeneration is the leading cause 
of severe vision loss in people over age 50. Although macu-
lar degeneration is almost never a totally blinding condition, 
it can be a source of significant visual disability. Age-related 
macular eye disease (AMD) is ranked third by WHO as a 
priority eye disease, following closely behind cataracts and 
glaucoma, and AMD is the primary cause of blindness in 
industrialized countries. Macular Pigment Optical Density 
(MPOD) is a biomarker for eye health. In the Age-Related 
Eye Disease Study II (AREDS II) it was demonstrated that 
lutein and zeaxanthin supplementation reduced the risk of 
progression of Advanced AMD (AAMD) [2]. When people 
taking lutein and zeaxanthin (L/Z) alone or in combination 
with omega-3 fatty acids, i.e., DHA/EPA, were compared 
with people not taking L/Z they observed a 10% reduction of 
progression to AAMD in favour of L/Z. Additionally impor-
tant when the analysis was conducted based on the level 
of L/Z dietary intake at baseline, the study demonstrated a 
26% reduction in the risk of progression to AAMD for L/Z 
in persons with the lowest dietary intake of L/Z. A similar 
beneficial effect was also observed for cataracts. A recent 
assessment for the EU showed that a total potential of €6.20 
billion in avoidable medical costs per year could be realized 
if all AMD patients used lutein and zeaxanthin supplement 
[54].
Cognitive impairment is a growing issue in the elderly. As 
people age (over 60 years) the brain starts to shrink at a rate 
of ~ 0.5%/year. Those with memory problems—‘mild cogni-
tive impairment’—show a faster rate of shrinkage of ~ 1.0%/
year and in patients with Alzheimer’s disease, the rate is 
higher still, at ~ 3%/year. B vitamin and omega-3 fatty acid 
status is inversely associated with the rate of shrinking of the 
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brain and memory decline [24]. Undoubtedly nutrition has 
an important role in preserving cognitive and mental health 
and thus improving quality of life in older age. The impact 
of specific nutritional factors on brain health in ageing is an 
area of active investigation worldwide. Emerging evidence 
implicates subclinical deficiencies of certain nutrients in 
cognitive decline and poor mental health in older adults; 
however, the threshold for nutrient levels to prevent or delay 
declining brain health is still unknown. If the findings of 
ongoing studies described—which show promise in rela-
tion to B-vitamins, omega-3 fatty acids and polyphenols—
are confirmed, a public health strategy to improve status of 
these key nutrients may help to achieve better cognitive and 
mental health in ageing. Future studies incorporating image-
ing techniques offer a robust basis for confirming effective 
nutrition interventions that could reduce the risk of cogni-
tive and mental decline in ageing and the related burden on 
health services.
Diabetes is a fast-growing issue globally and is a heavy 
burden for health care systems [22]. Diabetes is the num-
ber 4 risk factor for mortality. Micronutrients play a role 
in the development and the progression of diabetes. Due 
to the high prevalence of diabetes, a nutritional approach 
may be an important contribution to society. The “vitamin 
D and Type-2 diabetes” (D2d) study is a multi-centred, ran-
domized clinical trial in the US with the hypothesis that 
vitamin D supplementation may boost the body’s insulin 
production and processing. Study participants receive either 
vitamin D (4000 IU) supplement or placebo. The study is 
now complete, and currently data analysis is ongoing, with 
first results expected sometime in 2019 [60]. A nutritional 
solution could have a large impact on the quality of life for 
millions of people who are at risk for diabetes.
Health data from more than 190 countries show heart 
disease remains the number 1 global cause of death with 
17.3 million deaths each year [68]. Direct and indirect costs 
of cardiovascular diseases (CVD) and stroke total more 
than $320 billion. Nutrition and lifestyle interventions have 
been identified as preventive factors. In the VITamin D and 
OmegA-3 TriaL (VITAL) in the US, vitamin D and omega-3 
fatty acids were assessed for the prevention of cancer and 
CVD. Statistically significant reductions in secondary heart 
endpoints, including total and fatal myocardial infarctions 
(MI) and total coronary heart disease (CHD) in the omega-3 
arm (total MI had a 28% risk reduction, total CHD had a 
17% risk reduction, fatal MI had a 50% risk reduction) were 
achieved. The greatest reductions were observed in African 
Americans and those who do not eat a lot of fish. These 
results suggest that improving omega-3 status strengthens 
intrinsic capacity and provides a health benefit in primary 
prevention [40].
The loss of intrinsic capacity is associated with dysregu-
lated immune and inflammatory responses. In a human study 
it was demonstrated that increasing vitamin E status reduces 
the risk for infections in the upper respiratory tract in elderly 
[43]. The group with the higher dose of vitamin E had lower 
infections rates (all respiratory infections had a 35% risk 
reduction, upper respiratory tract infections had a 38% risk 
reduction, common cold had a 37% risk reduction).
In summary it can be stated that the strengthening of the 
intrinsic capacity is relevant for a healthy life and ageing. A 
healthy lifestyle with a balanced diet, including food fortifi-
cation and use of supplements providing all nutrients is one 
way to strengthen intrinsic capacity resulting in improved 
quality of life and healthy ageing. Monitoring trajectories 
across the life course is the recommended approach instead 
of waiting for the onset of disease(s). Intake recommenda-
tions for micronutrients (as part of a healthy lifestyle) should 
be updated taking optimal levels into account.
The longevity revolution within a context 
of increasing inequalities
The world is ageing rapidly. A baby born in 2015, can expect 
to live to be 100—a trajectory that has been to this time 
a much rarer event. Life expectancy in a country such as 
Brazil was only 43 years in 1945—today, it is 77 years. This 
extraordinary achievement—termed, the longevity revolu-
tion (LR)—will result in a tenfold increase in the world-
wide 60 + population between 1950 and 2050. By 2050, the 
80 + age group will have increased 27 times. In the same 
time period, the total population will only have increased 
3.7 times.
But it is not only the speed of the LR that is so remarkable 
and challenging. It is also the context to that ageing. Devel-
oped countries first experienced wealth, and then became 
aged. In contrast, developing countries are ageing much 
faster and within a context of persistent levels of hardship. 
For example, in France the percentage of 60 + has doubled 
since 1850, while in Brazil, Thailand, and China the same 
doubling will take a mere 20 years (before 2030).
Social and economic inequalities are major contributors 
to the health disparities that have led to rapid (or premature) 
ageing in many developing countries. In these countries, pre-
mature ageing is characterised by high rates of preventable 
(non-communicable) disease, injury, and social exclusion. 
This has implications at both the individual and popula-
tion levels, as both intrinsic capacity (a composite of all 
the physical and mental attributes on which an individual 
can draw—WHO) and functional ability (the health-related 
attributes that enable people to be and to do what they have 
reason to value—WHO) are adversely affected.
But ageing and health disparities can affect even wealthy 
developed countries. For example, the US boasts the larg-
est economy in the world but ranks 32 on life expectancy at 
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birth (LEB) due to drastic social and health inequalities. In 
fact, the US LEB is even on the decline, and has shown signs 
of reversing secular trends.
Examples of policies aimed at providing better standards 
include New Zealand, which recently announced a commit-
ment to national wellbeing, and South Australia, which cre-
ated a Centre for Well-Being and Resilience back in 2013. 
Despite these strides, the “modern plagues”—over nutri-
tion, obesity, non-communicable diseases (NCD’s)—remain 
widespread, and all of which could be mitigated or prevented 
through appropriate policies that promote a healthy diet.
Policies to support individuals to age healthfully, include, 
but go beyond appropriate nutrition and health policies. 
Appropriate policies are needed throughout the life course. 
The earlier the better but it is never too late is a mantra that 
everyone should embrace.
In fact, this mantra applies to the four “capitals” that we 
need to accumulate as we age: vital (health); knowledge (life-
long learning); social (participation) and financial capital 
(security). Individuals must bear a lot of the responsibility 
to make appropriate adjustments to their life trajectories but 
without robust public policies to make the good choices, the 
easy and more affordable choices, their efforts will be con-
stantly undermined. If and when that is done, we will be on 
the road to developing a genuine culture of care that is vital 
for our fast ageing populations and is commensurate with a 
truly modern society (see Fig. 3).
Conclusion
Global population data demonstrate that humans are indeed 
living longer, with many countries and population subsets 
living 30 years longer than just a century ago. However, 
this increase in lifespan has not always been paralleled by 
improvements in healthspan. Failure to recognize the differ-
ing nutritional and health needs of the aged, and burdened by 
social and economic inequalities, a rapidly ageing popula-
tion has also experienced increased rates of non-communi-
cable disease and healthcare costs. Healthspan rather than 
lifespan, needs to be recognized as the goal for all stages of 
a society, optimizing the quality and capabilities such that 
our final years are not faced with unnecessary deterioration 
and trepidation, but anticipation as active contributors to 
society. A combination of policies aimed at reducing social 
inequalities with innovative nutritional approaches have the 
potential to delay premature ageing and improve healthspan.
The World Health Organization is proposing the “Dec-
ade of Healthy Ageing 2020–2030” [71] to “explore syner-
gies between policy instruments to catalyze meaningful and 
measurable impact to improve older peoples’ lives”. The 
reader is encouraged to visit WHO’s website, read the call-
to-action spelled out in the 2015 WHO Global Strategy and 
Action Plan on Ageing and Health 2016–2030 and engage 
in the conversation [70]. This strategic approach, includ-
ing appropriate, science-based nutritional interventions, 
should be developed and adapted for use in all countries 
independent of their level of economic development to sup-
port healthy ageing throughout the lifespan.
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